Esbriet, Ofev Not Cost-effective IPF Treatment in US, Study Reports
Anti-fibrotic medications, such as Esbriet (pirfenidone) and Ofev (nintedanib), are not cost-effective treatments for idiopathic pulmonary fibrosis (IPF) in the U.S. due to their high prices, even though they remain the only effective therapies, according to a recent study. The study, “Cost-effectiveness of the anti-fibrotics for…